Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

63.77
BATS BZX Real-Time Price
As of 10:48am ET
 +2.46 / +4.01%
Today’s Change
46.52
Today|||52-Week Range
91.35
-9.30%
Year-to-Date
What's in Store for Vertex (VRTX) this Earnings Season?
Apr 24 / Zacks.com - Paid Partner Content
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
Apr 19 / Zacks.com - Paid Partner Content
What's in Store for AbbVie (ABBV) this Earnings Season?
Apr 21 / Zacks.com - Paid Partner Content
Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data
Apr 19 / TheStreet.com - Paid Partner Content
Company News for April 20, 2017
Apr 20 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close61.31
Today’s open62.34
Day’s range62.33 - 64.00
Volume7,137
Average volume (3 months)540,427
Market cap$2.6B
Dividend yield--
Data as of 10:48am ET, 04/25/2017

Growth & Valuation

Earnings growth (last year)-56.82%
Earnings growth (this year)-13.85%
Earnings growth (next 5 years)+53.36%
Revenue growth (last year)--
P/E ratioNM
Price/Sales20,927.50
Price/Book5.33

Competitors

 Today’s
change
Today’s
% change
CLVSClovis Oncology Inc+1.74+3.06%
IRWDIronwood Pharmaceuti...+0.16+0.96%
HZNPHorizon Pharma PLC+0.06+0.36%
ENDPEndo International P...-0.05-0.46%
Data as of 10:49am ET, 04/25/2017

Financials

Next reporting dateMay 15, 2017
EPS forecast (this quarter)-$1.71
Annual revenue (last year)$133.0K
Annual profit (last year)-$245.9M
Net profit margin-184,867.67%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Emil D. Kakkis
CFO, Senior VP &
Head-Investor Relations
Shalini Sharp
Corporate headquarters
Novato, California

Forecasts


Search for Jobs